ProfileGDS5678 / 1448963_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 85% 83% 85% 85% 82% 84% 84% 84% 85% 84% 84% 84% 85% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.2516685
GSM967853U87-EV human glioblastoma xenograft - Control 26.096483
GSM967854U87-EV human glioblastoma xenograft - Control 36.3369285
GSM967855U87-EV human glioblastoma xenograft - Control 46.5983385
GSM967856U87-EV human glioblastoma xenograft - Control 55.9986182
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.9698684
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.0568684
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.1946684
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.3872485
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.2612584
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.2240184
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.2193284
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.3479685
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.2205384